1r1w › Citations

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a.

Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, Rusconi L, Cristiani C
Proc Natl Acad Sci U S A 100 12654-9 (2003)
Cited: 80 times
EuropePMC logo PMID: 14559966

Abstract

The protooncogene c-met codes for the hepatocyte growth factor receptor tyrosine kinase. Binding of its ligand, hepatocyte growth factor/scatter factor, stimulates receptor autophosphorylation, which leads to pleiotropic downstream signaling events in epithelial cells, including cell growth, motility, and invasion. These events are mediated by interaction of cytoplasmic effectors, generally through Src homology 2 (SH2) domains, with two phosphotyrosine-containing sequence motifs in the unique C-terminal tail of c-Met (supersite). There is a strong link between aberrant c-Met activity and oncogenesis, which makes this kinase an important cancer drug target. The furanosylated indolocarbazole K-252a belongs to a family of microbial alkaloids that also includes staurosporine. It was recently shown to be a potent inhibitor of c-Met. Here we report the crystal structures of an unphosphorylated c-Met kinase domain harboring a human cancer mutation and its complex with K-252a at 1.8-A resolution. The structure follows the well established architecture of protein kinases. It adopts a unique, inhibitory conformation of the activation loop, a catalytically noncompetent orientation of helix alphaC, and reveals the complete C-terminal docking site. The first SH2-binding motif (1349YVHV) adopts an extended conformation, whereas the second motif (1356YVNV), a binding site for Grb2-SH2, folds as a type II Beta-turn. The intermediate portion of the supersite (1353NATY) assumes a type I Beta-turn conformation as in an Shc-phosphotyrosine binding domain peptide complex. K-252a is bound in the adenosine pocket with an analogous binding mode to those observed in previously reported structures of protein kinases in complex with staurosporine.

Reviews - 1r1w mentioned but not cited (2)

  1. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J. Mol Cell 42 9-22 (2011)
  2. MET: a critical player in tumorigenesis and therapeutic target. Graveel CR, Tolbert D, Vande Woude GF. Cold Spring Harb Perspect Biol 5 a009209 (2013)

Articles - 1r1w mentioned but not cited (9)

  1. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, Rusconi L, Cristiani C. Proc Natl Acad Sci U S A 100 12654-12659 (2003)
  2. Why Some Targets Benefit from beyond Rule of Five Drugs. Egbert M, Whitty A, Keserű GM, Vajda S. J Med Chem 62 10005-10025 (2019)
  3. Structural basis for selective small molecule kinase inhibition of activated c-Met. Rickert KW, Patel SB, Allison TJ, Byrne NJ, Darke PL, Ford RE, Guerin DJ, Hall DL, Kornienko M, Lu J, Munshi SK, Reid JC, Shipman JM, Stanton EF, Wilson KJ, Young JR, Soisson SM, Lumb KJ. J Biol Chem 286 11218-11225 (2011)
  4. Alchemical absolute protein-ligand binding free energies for drug design. Khalak Y, Tresadern G, Aldeghi M, Baumann HM, Mobley DL, de Groot BL, Gapsys V. Chem Sci 12 13958-13971 (2021)
  5. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments. Wang DD, Ma L, Wong MP, Lee VH, Yan H. PLoS One 10 e0128360 (2015)
  6. Identification of Cryptic Binding Sites Using MixMD with Standard and Accelerated Molecular Dynamics. Smith RD, Carlson HA. J Chem Inf Model 61 1287-1299 (2021)
  7. SSnet: A Deep Learning Approach for Protein-Ligand Interaction Prediction. Verma N, Qu X, Trozzi F, Elsaied M, Karki N, Tao Y, Zoltowski B, Larson EC, Kraka E. Int J Mol Sci 22 1392 (2021)
  8. Coarse-graining protein structures into their dynamic communities with DCI, a dynamic community identifier. Kumar A, Khade PM, Dorman KS, Jernigan RL. Bioinformatics 38 2727-2733 (2022)
  9. In Silico Target Identification of Galangin, as an Herbal Flavonoid against Cholangiocarcinoma. Balasubramanian B, Venkatraman S, Myint KZ, Krobthong S, Wongtrakoongate P, Sripa J, Rattanasinganchan P, Metheenukul P, Tohtong R. Molecules 27 4664 (2022)


Reviews citing this publication (27)

  1. Targeting MET in cancer: rationale and progress. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Nat Rev Cancer 12 89-103 (2012)
  2. Regulation of protein kinases; controlling activity through activation segment conformation. Nolen B, Taylor S, Ghosh G. Mol Cell 15 661-675 (2004)
  3. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Christensen JG, Burrows J, Salgia R. Cancer Lett 225 1-26 (2005)
  4. Hepatocyte growth factor twenty years on: Much more than a growth factor. Nakamura T, Sakai K, Nakamura T, Matsumoto K. J Gastroenterol Hepatol 26 Suppl 1 188-202 (2011)
  5. MET: a promising anticancer therapeutic target. Peters S, Adjei AA. Nat Rev Clin Oncol 9 314-326 (2012)
  6. Targeting RTK Signaling Pathways in Cancer. Regad T. Cancers (Basel) 7 1758-1784 (2015)
  7. Indolocarbazole natural products: occurrence, biosynthesis, and biological activity. Sánchez C, Méndez C, Salas JA. Nat Prod Rep 23 1007-1045 (2006)
  8. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. Yuan J, Dong X, Yap J, Hu J. J Hematol Oncol 13 113 (2020)
  9. Protein kinase inhibition of clinically important staurosporine analogues. Gani OA, Engh RA. Nat Prod Rep 27 489-498 (2010)
  10. Cancer driver mutations in protein kinase genes. Torkamani A, Verkhivker G, Schork NJ. Cancer Lett 281 117-127 (2009)
  11. Genetic predisposition to kidney cancer. Schmidt LS, Linehan WM. Semin Oncol 43 566-574 (2016)
  12. Hepatocyte growth factor and Met in drug discovery. Sakai K, Aoki S, Matsumoto K. J Biochem 157 271-284 (2015)
  13. Small molecule c-Met kinase inhibitors: a review of recent patents. Porter J. Expert Opin Ther Pat 20 159-177 (2010)
  14. Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. Cortot AB, Kherrouche Z, Descarpentries C, Wislez M, Baldacci S, Furlan A, Tulasne D. J Natl Cancer Inst 109 (2017)
  15. cMET Exon 14 Skipping: From the Structure to the Clinic. Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C. J Thorac Oncol 11 1423-1432 (2016)
  16. The multiple paths towards MET receptor addiction in cancer. Duplaquet L, Kherrouche Z, Baldacci S, Jamme P, Cortot AB, Copin MC, Tulasne D. Oncogene 37 3200-3215 (2018)
  17. Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer. Hong L, Zhang J, Heymach JV, Le X. Ther Adv Med Oncol 13 1758835921992976 (2021)
  18. MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk. Modica C, Tortarolo D, Comoglio PM, Basilico C, Vigna E. Int J Mol Sci 19 E3920 (2018)
  19. Impact of the Protein Data Bank on antineoplastic approvals. Westbrook JD, Soskind R, Hudson BP, Burley SK. Drug Discov Today 25 837-850 (2020)
  20. MET inhibitors in combination with other therapies in non-small cell lung cancer. Padda S, Neal JW, Wakelee HA. Transl Lung Cancer Res 1 238-253 (2012)
  21. Locus of fragility in robust breast cancer system. Radisavljevic Z. J Cell Biochem 92 1020-1024 (2004)
  22. The Exploration of Chirality for Improved Druggability within the Human Kinome. Saha D, Kharbanda A, Yan W, Lakkaniga NR, Frett B, Li HY. J Med Chem 63 441-469 (2020)
  23. Trends in the development of MET inhibitors for hepatocellular carcinoma. Okuma HS, Kondo S. Future Oncol 12 1275-1286 (2016)
  24. Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase. Fernandes M, Duplaquet L, Tulasne D. BMB Rep 52 239-249 (2019)
  25. When the MET receptor kicks in to resist targeted therapies. Fernandes M, Jamme P, Cortot AB, Kherrouche Z, Tulasne D. Oncogene 40 4061-4078 (2021)
  26. [Thirty years of Met receptor research: from the discovery of an oncogene to the development of targeted therapies]. Montagne R, Furlan A, Kherrouche Z, Tulasne D. Med Sci (Paris) 30 864-873 (2014)
  27. State of the structure address on MET receptor activation by HGF. Linossi EM, Estevam GO, Oshima M, Fraser JS, Collisson EA, Jura N. Biochem Soc Trans 49 645-661 (2021)

Articles citing this publication (42)

  1. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R, Bearss D. Oncogene 26 3909-3919 (2007)
  2. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. Oncogene 23 5387-5393 (2004)
  3. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, Froning KJ, Gao X, Hendle J, Keegan K, Leon BC, Müller-Dieckmann HJ, Nienaber VL, Noland BW, Post K, Rajashankar KR, Ramos A, Russell M, Burley SK, Buchanan SG. J Biol Chem 279 55827-55832 (2004)
  4. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC. J Biol Chem 286 20666-20676 (2011)
  5. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I. J Biol Chem 283 2675-2683 (2008)
  6. Sequence and structure signatures of cancer mutation hotspots in protein kinases. Dixit A, Yi L, Gowthaman R, Torkamani A, Schork NJ, Verkhivker GM. PLoS One 4 e7485 (2009)
  7. A crystallographic snapshot of tyrosine trans-phosphorylation in action. Chen H, Xu CF, Ma J, Eliseenkova AV, Li W, Pollock PM, Pitteloud N, Miller WT, Neubert TA, Mohammadi M. Proc Natl Acad Sci U S A 105 19660-19665 (2008)
  8. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Wang W, Marimuthu A, Tsai J, Kumar A, Krupka HI, Zhang C, Powell B, Suzuki Y, Nguyen H, Tabrizizad M, Luu C, West BL. Proc Natl Acad Sci U S A 103 3563-3568 (2006)
  9. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. Jacobs MD, Caron PR, Hare BJ. Proteins 70 1451-1460 (2008)
  10. Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. Dixit A, Torkamani A, Schork NJ, Verkhivker G. Biophys J 96 858-874 (2009)
  11. CAS directly interacts with vinculin to control mechanosensing and focal adhesion dynamics. Janoštiak R, Brábek J, Auernheimer V, Tatárová Z, Lautscham LA, Dey T, Gemperle J, Merkel R, Goldmann WH, Fabry B, Rösel D. Cell Mol Life Sci 71 727-744 (2014)
  12. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. Wang SY, Chen B, Zhan YQ, Xu WX, Li CY, Yang RF, Zheng H, Yue PB, Larsen SH, Sun HB, Yang X. J Hepatol 41 267-273 (2004)
  13. Structure of the human protein kinase MPSK1 reveals an atypical activation loop architecture. Eswaran J, Bernad A, Ligos JM, Guinea B, Debreczeni JE, Sobott F, Parker SA, Najmanovich R, Turk BE, Knapp S. Structure 16 115-124 (2008)
  14. Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase. Porter J, Lumb S, Lecomte F, Reuberson J, Foley A, Calmiano M, le Riche K, Edwards H, Delgado J, Franklin RJ, Gascon-Simorte JM, Maloney A, Meier C, Batchelor M. Bioorg Med Chem Lett 19 397-400 (2009)
  15. Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases. Xu Q, Malecka KL, Fink L, Jordan EJ, Duffy E, Kolander S, Peterson JR, Dunbrack RL. Sci Signal 8 rs13 (2015)
  16. Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors. Dorsch D, Schadt O, Stieber F, Meyring M, Grädler U, Bladt F, Friese-Hamim M, Knühl C, Pehl U, Blaukat A. Bioorg Med Chem Lett 25 1597-1602 (2015)
  17. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Hong SW, Jung KH, Park BH, Zheng HM, Lee HS, Choi MJ, Yun JI, Kang NS, Lee J, Hong SS. Cancer Lett 332 74-82 (2013)
  18. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Lountos GT, Tropea JE, Zhang D, Jobson AG, Pommier Y, Shoemaker RH, Waugh DS. Protein Sci 18 92-100 (2009)
  19. AAK1 identified as an inhibitor of neuregulin-1/ErbB4-dependent neurotrophic factor signaling using integrative chemical genomics and proteomics. Kuai L, Ong SE, Madison JM, Wang X, Duvall JR, Lewis TA, Luce CJ, Conner SD, Pearlman DA, Wood JL, Schreiber SL, Carr SA, Scolnick EM, Haggarty SJ. Chem Biol 18 891-906 (2011)
  20. Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. Zimmer Y, Vaseva AV, Medová M, Streit B, Blank-Liss W, Greiner RH, Schiering N, Aebersold DM. Cancer Lett 289 228-236 (2010)
  21. Discovery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors. Cho SY, Han SY, Ha JD, Ryu JW, Lee CO, Jung H, Kang NS, Kim HR, Koh JS, Lee J. Bioorg Med Chem Lett 20 4223-4227 (2010)
  22. The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion. Mady MS, Mohyeldin MM, Ebrahim HY, Elsayed HE, Houssen WE, Haggag EG, Soliman RF, El Sayed KA. Bioorg Med Chem 24 113-122 (2016)
  23. Identification of conserved polar residues important for salt tolerance by the Na+/H+ exchanger of Schizosaccharomyces pombe. Fliegel L. Mol Cell Biochem 268 83-92 (2005)
  24. A new Met inhibitory-scaffold identified by a focused forward chemical biological screen. Patané S, Pietrancosta N, Hassani H, Leroux V, Maigret B, Kraus JL, Dono R, Maina F. Biochem Biophys Res Commun 375 184-189 (2008)
  25. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification. Du J, Wu X, Tong X, Wang X, Wei J, Yang Y, Chang Z, Mao Y, Shao YW, Liu B. Oncotarget 8 26281-26287 (2017)
  26. Acylated Iridoids and Rhamnopyranoses from Premna odorata (Lamiaceae) as Novel Mesenchymal-Epithelial Transition Factor Receptor Inhibitors for the Control of Breast Cancer. Elmaidomy AH, Mohyeldin MM, Ibrahim MM, Hassan HM, Amin E, Rateb ME, Hetta MH, El Sayed KA. Phytother Res 31 1546-1556 (2017)
  27. Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer. Mohyeldin MM, Busnena BA, Akl MR, Dragoi AM, Cardelli JA, El Sayed KA. Eur J Med Chem 118 299-315 (2016)
  28. Identification of Phytochemicals Targeting c-Met Kinase Domain using Consensus Docking and Molecular Dynamics Simulation Studies. Aliebrahimi S, Montasser Kouhsari S, Ostad SN, Arab SS, Karami L. Cell Biochem Biophys 76 135-145 (2018)
  29. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase. Abbas HA, Al-Marhabi AR, Eissa SI, Ammar YA. Bioorg Med Chem 23 6560-6572 (2015)
  30. Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis. Xing W, Ai J, Jin S, Shi Z, Peng X, Wang L, Ji Y, Lu D, Liu Y, Geng M, Hu Y. Eur J Med Chem 95 302-312 (2015)
  31. Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses. Wilson LJ, Malaviya R, Yang C, Argentieri R, Wang B, Chen X, Murray WV, Cavender D. Bioorg Med Chem Lett 19 3333-3338 (2009)
  32. TrkA kinase inhibitors from a library of modified and isosteric Staurosporine aglycone. Tripathy R, Angeles TS, Yang SX, Mallamo JP. Bioorg Med Chem Lett 18 3551-3555 (2008)
  33. 131 -Oxophorbine protopheophorbide A from Ziziphus lotus as a novel mesenchymal-epithelial transition factor receptor inhibitory lead for the control of breast tumor growth in vitro and in vivo. Souid S, Elsayed HE, Ebrahim HY, Mohyeldin MM, Siddique AB, Karoui H, El Sayed KA, Essafi-Benkhadir K. Mol Carcinog 57 1507-1524 (2018)
  34. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase. Zhao F, Zhang J, Zhang L, Hao Y, Shi C, Xia G, Yu J, Liu Y. Bioorg Med Chem 24 4281-4290 (2016)
  35. Pharmacophore Mapping Approach for Drug Target Identification: A Chemical Synthesis and in Silico Study on Novel Thiadiazole Compounds. Meshram RJ, Baladhye VB, Gacche RN, Karale BK, Gaikar RB. J Clin Diagn Res 11 KF01-KF08 (2017)
  36. Structure activity relationships of quinoxalin-2-one derivatives as platelet-derived growth factor-beta receptor (PDGFbeta R) inhibitors, derived from molecular modeling. Mori Y, Hirokawa T, Aoki K, Satomi H, Takeda S, Aburada M, Miyamoto K. Chem Pharm Bull (Tokyo) 56 682-687 (2008)
  37. Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain. Wang X, Yennawar N, Hankey PA. Cell Commun Signal 12 28 (2014)
  38. The synthesis of bioactive indolocarbazoles related to K-252a. Moffat D, Nichols CJ, Riley DA, Simpkins NS. Org Biomol Chem 3 2953-2975 (2005)
  39. MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis. Lu D, Nagelberg A, Chow JL, Chen YT, Michalchuk Q, Somwar R, Lockwood WW. Cancers (Basel) 14 1378 (2022)
  40. Network Toxicology and Molecular Docking to Investigate the Non-AChE Mechanisms of Organophosphate-Induced Neurodevelopmental Toxicity. Souza JADCR, Souza T, Quintans ILADCR, Farias D. Toxics 11 710 (2023)
  41. Case Reports Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report. Ferlicot S, Just PA, Compérat E, Rouleau E, Tissier F, Vaessen C, Richard S. Diagn Pathol 16 107 (2021)
  42. Identification of Inhibitors of the Tyrosine Kinase c-Met by Structure-Based Virtual Screening. Lemcke T, Dreher J, Rarey M, Totzke F, Schächtele C, Kubbutat MH, Kunick C. Mol Inform 30 145-150 (2011)


Quick links